Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Treatment Period	STARTED	Rivaroxaban (Xarelto, BAY59-7939)	1,002
Treatment Period	STARTED	Vitamin K Antagonist (VKA)	502
Treatment Period	Subjects Received Treatment	Rivaroxaban (Xarelto, BAY59-7939)	988
Treatment Period	Subjects Received Treatment	Vitamin K Antagonist (VKA)	499
Treatment Period	COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	846
Treatment Period	COMPLETED	Vitamin K Antagonist (VKA)	400
Treatment Period	NOT COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	156
Treatment Period	NOT COMPLETED	Vitamin K Antagonist (VKA)	102
30-day Safety Follow-up Period	STARTED	Rivaroxaban (Xarelto, BAY59-7939)	982
30-day Safety Follow-up Period	STARTED	Vitamin K Antagonist (VKA)	487
30-day Safety Follow-up Period	COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	924
30-day Safety Follow-up Period	COMPLETED	Vitamin K Antagonist (VKA)	446
30-day Safety Follow-up Period	NOT COMPLETED	Rivaroxaban (Xarelto, BAY59-7939)	58
30-day Safety Follow-up Period	NOT COMPLETED	Vitamin K Antagonist (VKA)	41

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01674647/flow